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licenses/by/4.0/).Abstract Background: There is a need to synthesise the results of numerous randomised
controlled trials evaluating the addition of therapies to androgen deprivation therapy
(ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic
review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone
(AAP) to ADT.
Methods: Using our framework for adaptive meta-analysis (FAME), we started the review
process before trials had been reported and worked collaboratively with trial investigators
to anticipate when eligible trial results would emerge. Thus, we could determine the earliest
opportunity for reliable meta-analysis and take account of unavailable trials in interpretingl Trials Unit at UCL, Meta-analysis Group, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
cl.ac.uk (L.H.M. Rydzewska).
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with mHSPC. We obtained results for the primary outcome of overall survival
(OS), secondary outcomes of clinical/radiological progression-free survival (PFS) and grade
IIIeIV and grade V toxicity direct from trial teams. Hazard ratios (HRs) for the effects of
AAP plus ADT on OS and PFS, Peto Odds Ratios (Peto ORs) for the effects on acute
toxicity and interaction HRs for the effects on OS by patient subgroups were combined across
trials using fixed-effect meta-analysis.
Findings: We identified three eligible trials, one of which was still recruiting (PEACE-1
(NCT01957436)). Results from the two remaining trials (LATITUDE (NCT01715285) and
STAMPEDE (NCT00268476)), representing 82% of all men randomised to AAP plus ADT
versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in
the risk of death with AAP plus ADT (HR Z 0.62, 95% confidence interval [CI] Z 0.53
e0.71, p Z 0.55  1010), that translates into a 14% absolute improvement in 3-year OS.
Despite differences in PFS definitions across trials, we also observed a consistent and highly
significant 55% reduction in the risk of clinical/radiological PFS (HR Z 0.45, 95% CI Z 0.
40e0.51, p Z 0.66  1036) with the addition of AAP, that translates to a 28% absolute
improvement at 3 years. There was no evidence of a difference in the OS benefit by
Gleason sum score, performance status or nodal status, but the size of the benefit may vary
by age. There were more grade IIIeIV acute cardiac, vascular and hepatic toxicities with
AAP plus ADT but no excess of other toxicities or death.
Interpretation: Adding AAP to ADT is a clinically effective treatment option for men with
mHSPC, offering an alternative to docetaxel for men who are starting treatment for the
first time. Future research will need to address which of these two agents or whether their
combination is most effective, and for whom.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
For decades, the standard of care for men with meta-
static, hormone-sensitive prostate cancer (mHSPC) has
been castration, also called androgen deprivation ther-
apy (ADT). This is achieved either surgically with
bilateral orchiectomy or medically with luteinising hor-
moneereleasing hormone (LHRH) agonists/antagonists
[1,2]. ADT produces responses in up to 95% of men, but
it is not curative and disease progresses in virtually all
patients [1]. Numerous randomised controlled trials
(RCTs) have evaluated, or are currently evaluating, the
addition of other therapies to ADT. These include,
cytotoxic chemotherapy, radium-223 and next genera-
tion androgen receptor axis inhibitors, including abir-
aterone acetate and enzalutamide [3e6]. There will be a
need to synthesise the results of these trials to determine
reliably which treatments are most effective. Thus, we
are conducting a series of systematic reviews under the
auspices of the Systemic Treatment Options for Prostate
Cancer (STOPCaP) collaboration.
Most systematic reviews use aggregate data (AD)
from publications and are retrospectively planned.
Consequently, they can suffer from reporting biases, be
unreliable and lag behind therapeutic developments,
thus failing to influence ongoing or new trials. There-
fore, we have developed a novel framework for adaptive
meta-analysis (FAME) [7] to determine the earliestopportunity for reliable AD meta-analysis. FAME is a
prospective and collaborative approach that takes all
relevant trials into account, whether published, unpub-
lished or ongoing, and is therefore more responsive to
emerging trial results. FAME highlighted that key trials
investigating the addition of abiraterone acetate plus
prednisone/prednisolone (AAP) to ADT in mHSPC
were due to report results, triggering the current sys-
tematic review and meta-analysis. The primary aim was
to assess the effects of AAP in combination with ADT
on overall survival (OS), progression and acute
treatment-related toxicity on men with mHSPC. Our
secondary aim was to investigate whether any effect of
AAP varies across different subgroups of men.
2. Methods
Methods for this systematic review and meta-analysis
were pre-specified in a protocol (PROSPERO registra-
tion: CRD42017058300) [8], and the review was con-
ducted in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines [9].
2.1. Framework for adaptive meta-analysis (FAME)
We have developed and successfully piloted FAME in
systematic reviews of docetaxel and bisphosphonates in
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this review, we have adopted the key principles of
FAME [7], which are to (1) start the review process
before all, or indeed most, trials have completed; (2)
identify all published, unpublished and ongoing eligible
trials; (3) work collaboratively with trial teams to
develop a detailed picture of how information and re-
sults are likely to accumulate from trials; (4) predict the
feasibility and timing of a reliable meta-analysis (based
on a large proportion of eligible patients being included,
power to detect a clinically meaningful effect and
reasonable follow-up); (5) take account of trials that
have not yet completed/reported in interpreting results
and (6) determine if an update is needed and whether it
should be based on AD or individual participant data
(IPD).
2.2. Trial eligibility
RCTs were eligible if they compared ADT plus AAP
versus ADT in men with mHSPC. Trials including other
additional agents (e.g. docetaxel or radiotherapy [RT])
were also eligible, provided the additional treatment was
given in both treatment and control arms. Those that
included additional treatments on the control arm only
were ineligible. Trials that randomised men who had
failed first-line hormone therapy for metastatic prostate
cancer or men with castrate-refractory prostate cancer
were also ineligible.
2.3. Trial identification
As part of the wider STOPCaP project, we regularly and
systematically searched a number of trial sources to
identify all published, unpublished and ongoing trials in
men with mHSPC. This provides a comprehensive and
up-to-date database of all RCTs eligible for all of our
STOPCaP systematic reviews. We also requested regular
updates from relevant trial teams on the status and
reporting plans. Trials pertinent to this particular review
of AAP were identified as part of this broader search.
With no restriction on language, LHMR, SB and
CLV searched MEDLINE, Embase, clinicaltrials.gov
and the Cochrane Central Register of Controlled
Trials to May 2017, using database-specific search
strategies [22,23] (Web Appendix 1). We also searched
proceedings from relevant conferences, such as the
American Society of Clinical Oncology, the European
Society for Medical Oncology, the European Cancer
Organisation, the American Urological Association and
the European Association of Urology to May 2017
(Web Table 1). In addition, reference lists of review
articles and bibliographies of identified trial reports were
screened for further eligible trials.
Once duplicates were removed, all relevant records
were independently assessed for eligibility by threereviewers (LHMR, SB and CLV). Full articles or pro-
tocols, where available, were obtained for records
deemed potentially eligible. All three reviewers agreed
the final set of eligible RCTs and determined which of
these were relevant specifically to this review of AAP.
Collaborators, including representatives from the man-
ufacturers of abiraterone acetate (Janssen), were also
asked to review, and where possible, supplement our
provisional list of eligible trials.
2.4. Outcomes
The primary outcome was OS, defined as the time from
randomisation to death from any cause. The secondary
outcomes were progression-free survival (PFS), defined
as the time from randomisation to first evidence of
symptomatic clinical progression or radiological pro-
gression or death (excluding biochemical (prostate-
specific antigen [PSA]) progression) and failure-free
survival (FFS), defined as time to first biochemical
(PSA), clinical or radiological progression. Further
secondary outcomes were grade IIIeIV and grade V
toxicity (as defined in each trial). These outcomes were
prospectively chosen because they were listed in the trial
protocols, and their definitions are sufficiently similar to
allow them to be combined across trials.
2.5. Data collection
For eligible trials, and for men with metastatic disease,
we sought information on the following: trial accrual
period, number of patients, patient age, PSA, perfor-
mance status, T and N category, location of metastases,
disease history, Gleason sum score and hormone ther-
apy from publications, protocols and directly from in-
vestigators. We also sought results overall for OS, PFS
and FFS as well as by patient subgroups, defined by age,
Gleason sum score, nodal status, performance status,
type of hormone therapy, location of metastases and
disease history. We also requested results for all grades
of acute treatment toxicity, as collected within trials, and
for the main grade IIIeIV categories, which we tried to
match across trials.
To assess the risk of bias of included trials, based on
the outcome of OS, we also sought information on the
method of randomisation sequence generation, alloca-
tion concealment, blinding of participants, personnel
and outcome assessment, completeness of outcome data
and whether all key outcomes were reported/available.
2.6. Planning the meta-analysis
Initial searches identified three eligible trials (Table 1).
In 2016, through contact with investigators, we antici-
pated that by 2017, one trial, PEACE-1 (NCT01957436)
would still be recruiting patients, but the two other
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(NCT00268476)) would be reporting results [11,12].
Based on recruitment information available at that
time, we predicted that the latter two trials would
represent over 70% of metastatic patients eligible for
this comparison. Given that these trials were large and
adequately powered and that PEACE-1 is unlikely to
produce results before 2020, this provided the trigger
to initiate an early systematic review and meta-
analysis. However, we also planned to take into
account the potential impact of the results of PEACE-1.
2.7. Measuring treatment effects and conducting the
meta-analysis
For time-to-event outcomes (OS and PFS), the hazard
ratios (HRs) and associated statistics from each trial
were sought directly from investigators. These were
combined using the fixed-effect model to give HRs
representing the overall risk of an event on AAP
compared with ADT [13]. For toxicity, the number of
grade IIIeIV toxicities and the number of patients were
sought directly from investigators. These were used to
calculate Peto odds ratio (Peto OR) estimates of treat-
ment effect [13] because this measure performs well
when event rates are low [14]. Peto OR estimates for the
individual trials were pooled across trials, using the
fixed-effect model, to give ORs representing the risk of
an event on AAP versus ADT. Chi-square tests and the
I2 statistic were used to assess the statistical heteroge-
neity [15].
We also planned to investigate whether any effect of
treatment on OS was consistent across patient sub-
groups including age (as defined in the trials), perfor-
mance status (0, 1þ), nodal status (N0, Nþ), Gleason
sum score (<8, 8), type of hormone therapy (orchi-
ectomy, LHRH-agonist or LHRH-antagonist), location
of metastases (bone, bone and soft tissue, or soft tissue
only) and disease history (de novo metastatic disease or
relapsed after prior local therapy with curative intent).
If there were insufficient numbers of men within any of
these subgroups, we either combined them to achieve
groups of a reasonable size or did not perform sub-
group analyses. If categories were incompatible across
trials, we worked to re-categorise the subgroups (e.g.
performance status 0, 1þ instead of 0e1, 2) and
requested trial subgroup analysis results based on these
new categories. For subgroup variables with two cate-
gories, an interaction HR was calculated from the ratio
of HRs derived from each trial’s subgroup analyses (e.g.
the HR for Gleason score <8 divided by the HR for
Gleason score 8). For subgroup variables with three
ordered categories, interaction HRs were estimated
using a weighted linear regression of subgroup HRs,
with the assumption that the error variances were
known. These interaction HRs were then combined
across trials using a fixed-effect meta-analysis [16,17]. Ifevidence of an interaction or difference in the size of
effect was found in a particular subgroup, we assessed
whether a similar meta-analysis on PFS, a potentially
more sensitive outcome, would support or refute the
findings.
All p-values are two-sided. All analyses were carried
out using Stata, version 14.2.
3. Results
Our broad searches for all trials in mHSPC retrieved
15,486 unique records, and we identified three trials
eligible for this particular review (Fig. 1). Two trials
(LATITUDE and STAMPEDE) compared AAP plus
ADT with ADT [11,12]; one of these (STAMPEDE) as
part of a multi-arm, multi-stage design [18]. Both have
recently published results (Table 1) [11,12]. Although
STAMPEDE includes men with both metastatic and
non-metastatic disease [12], we obtained information
and results for the patients with metastatic disease. The
third (PEACE-1) is a factorial trial investigating the
addition of AAP and/or RT to ADT and is still
accruing patients (Table 1). Moreover, the PEACE-1
protocol was amended in 2015 to allow docetaxel in
all arms, and since then, approximately two-thirds of
randomised men have received docetaxel in addition to
ADT, with one-third receiving ADT without docetaxel.
Thus, we have been able to include results for two trials
[11,12], which, accounting for the amended PEACE-1
protocol, represents 82% (2201/2677) of all men rand-
omised to AAP plus ADT versus ADT (without doce-
taxel in either arm), a higher percentage than originally
anticipated.
LATITUDE and STAMPEDE randomised men with
mHSPC between 2011 and 2014. In both trials, abir-
aterone acetate was administered as a single dose of
1000 mg per day together with prednisolone or predni-
sone (5 mg daily) to prevent secondary mineralocorti-
coid excess, until disease progression, withdrawal of
consent or unacceptable toxicity. Median follow-up was
30 months in LATITUDE and 41 months for men with
metastatic disease in STAMPEDE [11,12]. Based on
randomisation sequence generation, allocation conceal-
ment, blinding, completeness of outcome data and se-
lective outcome reporting, both trials were judged to
have a low risk of bias (Table 2).
All men in LATITUDE and 94% of men in STAM-
PEDE were classed as newly diagnosed with mHSPC
[11,12] and were receiving long-term ADT for the first
time, the remainder having relapsed after prior treat-
ment for localised disease. Most received LHRH-based
therapy (z86%) rather than orchiectomy. Across the
two trials, men were aged between 33 and 92 years
(LATITUDE median 67 years [interquartile range
(IQR) 61e73 years]; STAMPEDE median 67 years
[IQR 62e71 years]) mostly with a Gleason sum score of
8 (87%), good performance status (97% Eastern
Table 1
Characteristics of studies eligible trials.
Trial Accrual dates Number
of M1
patients
De novo or
relapsed M1?
Control Treatment Median
age
(range)
Gleason
score of
8e10 (%)
Performance
status
0e1 (%)
Median
follow-up
(survival)
STAMPEDE [12]
(Arm A versus arm G)
M1 patients only
11/2011e01/2014 1002 De novo
(95%) or
relapsed after
local therapy
(5%)
ADT (LHRH agonist
or antagonist or
orchiectomy)
ADTþ abiraterone (1000
mg/d)þ prednisone (5 mg/d)
67 (62
e72)
737 (74%) 988 (97%) 41 months
LATITUDE [11] 02/2013e12/2014 1199 De novo ADT (LHRH agonists
or orchiectomy)
ADTþ abiraterone (1000
mg/d)þ prednisone (5 mg/d)
67 (33
e92)
1170 (98%) 1157 (96%) 30.4 months
PEACE-1a (NCT01957436)
(patients not receiving
docetaxel in addition
to ADT)
11/2013eto date z476
expected
De novo ADT (LHRH agonist or
antagonist or orchiectomy)
ADTþ abiraterone (1000
mg/d)þ prednisone (10mg/d)
Not yet
available
Not yet
available
Not yet
available
Not yet
available
ADT (LHRH agonist or
antagonist or orchiectomy) þ
radiotherapy
(74 Gy, 37 fractions)
ADTþ abiraterone (1000
mg/d)þ prednisone (10mg/d)
þ radiotherapy (74 Gy,
37 fractions)
PEACE-1b (NCT01957436)
(patients receiving
docetaxel in addition
to ADT)
11/2015eongoing Target z650
(z300þ
accrued
to date)
ADT (LHRH agonist or
antagonist or orchiectomy) þ
docetaxelc (75 mg/m2 q 21 days;
6 cycles)
ADT þ docetaxelc þ
abiraterone (1000 mg/d) þ
prednisone (10 mg/d)
Not yet
available
Not yet
available
Not yet
available
Not yet
available
ADT (LHRH agonist or
antagonist or orchiectomy) þ
docetaxelc (75 mg/m2 q 21 days;
6 cycles) þ radiotherapy
(74 Gy, 37 fractions)
ADT þ docetaxelc þ
abiraterone (1000 mg/d) þ
prednisone
(10 mg/d) þ radiotherapy
(74 Gy, 37 fractions)
ADT, androgen deprivation therapy; LHRH, luteinising hormoneereleasing hormone.
a Patients randomised to PEACE-1, who have not received docetaxel in addition to ADT are eligible for this comparison.
b Patients randomised to PEACE-1, who have received docetaxel in addition to ADT will be eligible for a subsequent comparison of the
systematic review (PROSPERO CRD42017058300).
c Docetaxel use is left to the investigator’s discretion (stratification factor).
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Electronic databases searched (n=11,343 records retrieved)
MEDLINE (n=3,264)
Embase (n=4,850)
Cochrane CENTRAL (n=2,629)
Clinicaltrials.gov (n=630)
Duplicate records, across all databases (n=3,079)
Poten?ally eligible trials (n=3)
Unique records screened (n=8,294)
Not relevant comparison (n=8,291)
Eligible trials (n=3)
Included, eligible trials (n=2)
Eligible for review, but currently ongoing (n=1)
Conference proceedings searched (n=7,192 records retrieved)
ASCO (n=2,727)
ASCO GU (n=1,913)
AUA (n=1,342)
EAU (n=397)
ESMO / ECCO (n=813)
Unique records screened (n=7,192)
Poten?ally eligible trials (n=0)
Not relevant comparison (n=7,192)
Fig. 1. PRISMA flow diagram of trial identification, screening, eligibility and inclusion. ASCO, American Society of Clinical Oncology;
AUA, American Urological Association; EAU, European Association of Urology; ECCO, European Cancer Organisation; ESMO,
European Society for Medical Oncology; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
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tion 0e1) and positive pelvic nodes (52%) [11,12]. The
notable differences between the trials were that LATI-
TUDE included more men with a performance status of
1 (42% versus 24% in STAMPEDE), and with visceral,
soft tissue and nodal metastases (65% versus 35% in
STAMPEDE) with or without bone metastases [11,12].
Furthermore, as a Gleason sum score of 8 was one of
the eligibility criteria for the LATITUDE trial [11],
relatively few men with a Gleason score of <8 were
included (2% versus 23% in STAMPEDE) (Table 3).
Therefore, men in the LATITUDE trial were generally
higher risk patients with a greater burden of disease. The
LATITUDE trial results are from an interim analysis
conducted when approximately 50% of expected death
events had occurred, but after unanimous approval by
the Independent Data Monitoring Committee, the trial
was unblinded and the analysis is considered final [11].
For the primary outcome of OS, results were based
on all 2201 men with metastatic disease from the two
trials and included 774 deaths. Median OS in LATI-
TUDE is 34.7 months in the ADT arm, but it has not
yet been reached in the AAP arm. In STAMPEDE,
median OS is 48 months in the ADT arm and again has
not been reached in the AAP arm. Based on these data,
we found a highly significant 38% reduction in the risk
of death (HR Z 0.62, 95% CI Z 0.53e0.71,
p Z 0.55  1010; Fig. 2). Applying the HR to the
average control-group survival from LATITUDE andSTAMPEDE [11,12], translates to a 14% absolute
improvement in OS at 3 years with AAP, from 55% to
69%. The results across trials were remarkably consis-
tent, and there was no evidence of statistical heteroge-
neity (Heterogeneity chi2 Z 0.01, df Z 1, p Z 0.90,
I2 Z 0%).
The secondary outcome of PFS was defined differ-
ently in each of the two trials. In LATITUDE [11], this
was defined as the time to radiologically confirmed
progression or death by any cause, whereas in STAM-
PEDE, it was defined as the time to first symptomatic
clinical (defined as new cancer-related symptoms) or
radiological progression or death from prostate cancer
[12]. Despite these differences, we felt that the outcomes
were sufficiently compatible to combine. Results were
again available for all 2201 patients and included 1067
events. Median PFS in LATITUDE is 14.8 months in
the ADT arm and 33 months in the AAP arm. In
STAMPEDE, median PFS is 24 months in the ADT
arm and has not been reached in the AAP arm. Based on
these data, we observed a highly significant 55% reduc-
tion in the risk of clinical/radiological PFS (HRZ 0.45,
95% CI Z 0.40e0.51, p Z 0.66  1036; Fig. 2).
Applying the HR to the average control-group PFS
from LATITUDE and STAMPEDE translates to a 28%
absolute improvement in PFS at 3 years with AAP, from
30% to 58%. Although PFS was differently defined
across the two trials, individual trial results were very
consistent, with no evidence of statistical heterogeneity
Table 2
Assessment of risk of bias (based on overall survival).
Trial ID Adequate sequence
generation
Allocation concealment Masking Incomplete
outcome data
addressed
Free of selective
reporting
STAMPEDE [12] Central randomisation
using a computerised
algorithm.
A minimisation method
with a random element
of 80% was used to
stratify for a number of
clinically important
factors
Central telephone
randomisation
Open label; blinding to
treatment allocation
considered impractical
and of limited value,
given the primary
outcome of death from
any cause
All randomised
patients included
in analyses
All outcomes of
interest reported
LATITUDE [11] A computer-generated
randomisation schedule
was used. Country by
country randomisation
was performed using
permuted block
randomisation.
Centralised interactive
Web response system
(IWRS)
Double blind, placebo
controlled. Participants,
care-givers and
investigators unaware of
treatment allocation
All randomised
patients included
in analyses
All outcomes of
interest reported
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We were unable to assess FFS, as only one of the trials
(STAMPEDE) analysed this outcome [12].
As most men were newly diagnosed and received
LHRH-based ADT, there was no value in conducting
subgroup analyses by disease history and type of ADT.
Likewise, for results based on location of metastases,
clear overlap between sites of metastases meant that
these could not be meaningfully combined in a meta-
analysis. We did not observe any variation in the effect
of treatment on OS by Gleason sum score (interaction
HR Z 0.81, 95% CI Z 0.48e1.36, p Z 0.42), perfor-
mance status (interaction HR Z 0.85, 95%
CI Z 0.63e1.16, p Z 0.31) or nodal status (interaction
HRZ 0.95, 95% CIZ 0.67e1.34, pZ 0.77; Fig. 3). For
the outcome of OS, there was evidence that the size of
benefit was greater in younger men and less pronounced
in older men, both when age groups were defined as in
the STAMPEDE trial (<70, 70: interaction
HR Z 1.54, 95% CI Z 1.14e2.08, p Z 0.005) [12] and
when the categories were amended to achieve a broader
distribution of men across age groups (<65, 65e75,
>75: interaction HR Z 1.24, 95% CI Z 1.02e1.52,
p Z 0.033; Fig. 4). However, this pattern was less clear
when based on PFS (<70, 70: interaction HRZ 1.30,
95% CI Z 1.00e1.69, p Z 0.05; <65, 65e75, >75:
interaction HRZ 1.15, 95% CIZ 0.95e1.38, pZ 0.14;
Web Fig. 1).
We obtained all available grade IIIeIV toxicity data,
from both trials, and across all categories, but it should
be noted that the majority of these were grade III
toxicities. Although both trials used the Common
Terminology Criteria for Adverse Events (CTCAE,
version 4.0), there was some variation in the types of
events underpinning the main toxicity categories.
Where these were deemed sufficiently similar across
trials (musculoskeletal, gastrointestinal, respiratory andgeneral disorders), results were combined in meta-
analysis. However, as LATITUDE analysed cardiac
and vascular toxicities separately, whereas these were
combined in STAMPEDE, the STAMPEDE team
provided additional results for cardiac and vascular
toxicities separately [11,12]. Similarly, the LATITUDE
team provided further results to facilitate pooling of
hepatic toxicity as defined in the STAMPEDE trial
[11,12]. We were unable to combine other grade IIIeIV
toxicities that had been observed in considerable
numbers in the individual trials (e.g. endocrine, meta-
bolic disorders and nervous system disorders) in meta-
analysis [11,12]. Overall, we found no increase in grade
IIIeIV musculoskeletal, gastrointestinal, respiratory or
general disorders with the addition of AAP (Fig. 5).
However, there was an approximate three-fold increase
in grade IIIeIV acute cardiac (Peto ORZ 2.93, 95% CI
1.74e4.93, p < 0.001) and hepatic toxicity (Peto
OR Z 3.09, 95% CI 2.12e4.50, p < 0.001) and an
approximate two-fold increase in grade IIIeIV
vascular events (OR Z 2.28, 95% CI 1.71e3.03,
p < 0.001), the majority of which (90%) were related
to hypertension.
Across the two trials, there were 61 deaths associated
with grade V adverse events but no clear evidence that
these were increased with the addition of AAP (Peto
OR Z 1.37 95% CI 0.82e2.29, p Z 0.23; Fig. 5).
4. Discussion
4.1. Summary of results
We have shown that adding AAP to ADT provides
highly significant and substantial reductions in the risk
of both death (38%) and clinical/radiological PFS
(55%) for men with mHSPC. These translate into 14%
and 28% absolute improvements in OS and PFS,
Table 3
Characteristics of included patients.
STAMPEDE LATITUDE
ADT ADT þ AAP ADT ADT þ AAP
Number of patients 502 500 602 597
Age
Median (IQR) 67 (62e72) 67 (62e71) 67 (61e73) 68 (61e73)
Range 39e84 42e85 33e92 38e89
PSA [ng/ml]
Median (IQR) 97 (26e358) 96 (29e371) 23.05 (4.96e112.66) 25.43 (4.62, 117.58)
Range 0e10530 0e21460 (0.1e8889.6) (0e87775.9)
Time from initial diagnosisa
Median 2.3 2.5 2.0 1.8
Range 0e160 0e177 (0e4) (0e3)
Missing 1 3 0 0
WHO PS (ECOG PS)
0 370 (73.7%) 374 (74.8%) 331 (55.0%) 326 (54.6%)
1 125 (24.9%) 119 (23.8%) 255 (42.4%) 245 (41.0%)
2 7 (1.4%) 7 (1.4%) 16 (2.7%) 26 (4.4%)
T categoryb
T0 1 (0.2%) 2 (0.4%) 1 (0.2%) 0
T1 10 (2.0%) 5 (1%) 25 (4.2%) 29 (4.9%)
T2 45 (9.0%) 44 (8.8%) 113 (18.8%) 94 (15.8%)
T3 270 (53.8%) 288 (57.6%) 254 (42.3%) 246 (41.3%)
T4 137 (27.3%) 118 (23.6%) 128 (21.3%) 159 (26.7%)
Tx 39 (7.8%) 43 (9.2%) 80 (13.3%) 68 (11.4%)
N categoryc
N0 175 (34.9%) 167 (33.4%) 151 (25.2%) 152 (25.5%)
Nþ 291 (58.0%) 292 (58.4%) 280 (46.7%) 280 (47.0%)
Nx 36 (7.2%) 41 (8.2%) 169 (28.2%) 164 (27.5%)
Location of metastases
Bone 448 (89.2%) 434 (86.8%) 585 (97.5%) 580 (97.3%)
Liver 8 (1.6%) 7 (1.4%) 30 (5.0%) 32 (5.4%)
Lung 21 (4.2%) 21 (4.2%) 72 (12.0%) 73 (12.2%)
Nodal 150 (29.9%) 142 (28.4%) 287 (47.8%) 283 (47.5%)
Other 26 (5.2%) 23 (4.6%) 182 (30.4%) 180 (30.1%)
Disease history (newly diagnosed/relapsed)
Newly diagnosed M1 476 (94.8%) 465 (93%) 602 (100%) 597 (100%)
Previously treated M1 26 (5.2%) 35 (7.0%) 0 0
Gleason sum
7 119 (23.7%) 115 (23%) 16 (2.7%) 13 (2.2%)
8e10 373 (74.3%) 364 (72.8%) 586 (97.3%) 584 (97.8%)
Unknown 10 (2.0%) 21 (4.2%) 0 0
Type of ADTd
Orchiectomy 3 (0.6%) 3 (0.6%) 71 (11.8%) 73 (12.2%)
Bicalutamide/anti-androgen alone 1 (0.2%) 0 84 (14.0%) 46 (7.7%)
Dual androgen blockade 3 (0.6%) 1 (0.2%) NA NA
LHRH based 495 (98.6%) 496 (99.2%) 450 (74.8%) 449 (75.2%)
AAP, abiraterone acetate plus prednisone/prednisolone; ADT, androgen deprivation therapy; ECOG, Eastern Cooperative Oncology Group;
LHRH, luteinising hormoneereleasing hormone; PS, performance score; WHO, World Health Organisation.
a For STAMPEDE, this also includes men who have relapsed after previous radical treatment.
b In LATITUDE, T category unaccounted for in one patient from each arm.
c In LATITUDE, N category unaccounted for in two patients in ADT arm and one patient in ADT þ AAP.
d In LATITUDE, in ADT arm, some patients may have received anti-androgen in addition to LHRHa-based treatment; the patients unac-
counted for in ADT þ AAP may not yet have been started on ADT as diagnosed only very recently.
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benefit did not vary by Gleason sum score, performance
status or nodal status. Although our results suggest that
the observed survival benefit may be greater in younger
men and lesser in older men, the sample size in this latter
group is small. In addition, for PFS there was less evi-
dence that the treatment effect varied with age. Based on
the data available, acute grade IIIeIV cardiac, hepatic
and to a lesser degree vascular toxicities, were increasedwith the use of AAP. There was no statistically signifi-
cant excess of deaths associated with use of AAP.
4.2. Strengths
This is the first systematic review of adding AAP to
ADT in the mHSPC setting and includes data on 2201
men from two large trials [11,12], representing 82% of all
men randomised to ADT plus AAP versus ADT
name
Trial
Overall
LATITUDE
STAMPEDE
events/patients
AAP+ADT
319/1097
169/597
150/500
events/patients
ADT
455/1104
237/602
218/502
(95% CI)
Hazard Ratio
0.62 (0.53, 0.71)
0.62 (0.51, 0.76)
0.61 (0.49, 0.75)
Weight
%
53.66
46.34
Favours AAP+ADT Favours ADT
.25 .5 1
name
Trial
Overall
LATITUDE
STAMPEDE
events/patients
AAP+ADT
412/1097
239/597
173/500
events/patients
ADT
655/1104
354/602
301/502
(95% CI)
Hazard Ratio
0.45 (0.40, 0.51)
0.47 (0.39, 0.55)
0.43 (0.36, 0.52)
Weight
%
54.86
45.14
Favours AAP+ADT Favours ADT
.25 .5 1
A
B
Fig. 2. Effect of adding AAP to ADT on (A) overall survival and (clinical/radiological) progression-free survival (B) in men with mHSPC.
Each filled square denotes the HR for that trial comparison, with the horizontal lines showing the 95% CI. The size of the square is directly
proportional to the amount of information contributed by a trial. The diamond represents a (fixed-effect) meta-analysis of the trial HRs,
with the centre of this diamond indicating the HR and the extremities the 95% CI. AAP, abiraterone acetate plus prednisone/prednisolone;
ADT, androgen deprivation therapy; CI, confidence interval; HR, hazard ratio; mHSPC, metastatic hormone-sensitive prostate cancer.
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across trials are very clear, highly consistent and allow
us to provide very precise estimates of the direction and
size of effects. Therefore, these meta-analysis results
provide reliable and robust evidence to guide practice
and future research. Using our collaborative FAME
approach, we have been able to synthesise the effects of
adding AAP to ADT in a more timely, reliable, and
meaningful manner than is usually possible with aggre-
gate data [7]. We were able to identify all eligible trials,
in advance of results being available, anticipate when
results of STAMPEDE and LATITUDE were due to
emerge and obtain up-to-date accrual information for
the ongoing PEACE-1 trial [11,12]. The STOPCaP
Project Management Group also gained access to pre-
publication results and additional unreported analyses.
We obtained additional PFS results for men with met-
astatic disease from STAMPEDE, allowing us to
examine the consistency of effect across the two trials
and provide the best estimate of the sizes of the effect.
By obtaining subgroup analyses based on STAMPEDE
M1 patients and additional analyses of LATITUDE, we
were also able to investigate whether the effects of AAP
on OS and PFS are consistent across different types
of men, with far greater power than either individual
trial. By collecting acute toxicity and, where possible,
harmonising categories, we have been able to provide
the first formal analysis of grade III, IV and grade V
adverse events within and across trials. This has
confirmed that there is no increase in deaths, but shown
serious cardiac, vascular and hepatic adverse events are
exacerbated with AAP. In addition, the FAMEapproach has also allowed us to publish the review re-
sults in a similar time frame to the individual trial results
[11,12].
4.3. Limitations
As stated earlier, the LATITUDE trial results are from
a planned interim analysis, but after approval by the
Independent Data Monitoring Committee, are now
considered final [11]. The effect sizes observed in trials
that report early can lessen with longer follow-up du-
rations; however, the effect seen in LATITUDE showed
internal consistency across planned subgroup analyses
and is substantial and highly significant in its own
right [11]. Moreover, the results are consistent with the
final results of STAMPEDE [12], which were reported at
the pre-planned time. Although in LATITUDE, PFS
was defined as the time to radiologically confirmed
progression or death by any cause [11] and in STAM-
PEDE as the time to first symptomatic clinical or
radiological progression or death from prostate can-
cer [12], again, results were very consistent. The
apparent difference in the size of the OS benefit by age
may reflect that older men are at higher risk of dying
from other co-existing conditions or are less able to
tolerate treatments. However, to establish definitively
whether the effect of AAP varies with age will require an
analysis of age as a continuous variable, which affords
greater power but necessitates the collection of IPD.
Notably, all men recruited to LATITUDE and the
majority of men with metastatic disease recruited to
STAMPEDE had newly diagnosed disease [11,12].
N+
N0
LATITUDE
N+
N0
STAMPEDE
Nodal status
1-2
0
LATITUDE
1-2
0
STAMPEDE
Performance status
8-10
<8
LATITUDE
8-10
<8
STAMPEDE
Gleason sum score
by subgroup
Effect on survival
82/280
35/152
92/292
48/167
90/271
79/326
41/126
109/374
165/584
4/13
116/364
27/115
events/patients
AAP+ADT
124/280
50/151
133/291
70/175
129/271
108/331
71/132
147/370
230/586
7/16
179/373
34/119
events/patients
ADT
Favours
AAP+ADT
Favours
ADT
.5 1 2
HR (95% CI)
Interaction
0.95 (0.67, 1.34)
0.97 (0.58, 1.62)
0.94 (0.59, 1.49)
0.85 (0.63, 1.16)
0.95 (0.64, 1.42)
0.73 (0.46, 1.17)
0.81 (0.48, 1.36)
1.02 (0.29, 3.54)
0.77 (0.43, 1.37)
Weight
%
44.32
55.68
58.28
41.72
17.63
82.37
Greater treatment effect
with higher Gleason sum score,
worse PS, or
more nodal involvement
Lesser treatment effect
with higher Gleason sum score,
worse PS, or
more nodal involvement
.5 1 2
Fig. 3. Effect of adding AAP to ADT on overall survival by nodal status, Gleason sum score and performance status. Each filled square
denotes the HR for each subgroup of men defined by, Gleason sum score, nodal status and PS within each trial, with the horizontal lines
showing the 95% CI. The size of the square is directly proportional to the amount of information contributed by a subgroup. Each filled
circle denotes the HR for the interaction between the effect of chemotherapy and these subgroups for each trial, with the horizontal lines
showing the 95% CI. The size of each circle is directly proportional to the amount of information contributed by a trial. The open circle
represents a (fixed-effect) meta-analysis of the interaction HRs, with the horizontal line showing the 95% CI. AAP, abiraterone acetate
plus prednisone/prednisolone; ADT, androgen deprivation therapy; CI, confidence interval; HR, hazard ratio; PS, performance status.
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benefit in these men, there remains some uncertainty
about whether the benefits of AAP can be extrapolated
to men who have relapsed after prior local treatment for
localised disease. Furthermore, in LATITUDE [11], all
patients had high-risk metastatic disease, and most also
had a high burden (or volume) or disease while char-
acterisation of risk or burden of disease in STAMPEDE
is unknown. The retrospective assessment of disease
volume in STAMPEDE, combined with the planned
collection of IPD from the AAP and docetaxel trials in
mHSPC, may therefore help to determine whether ef-
fects vary by disease volume [12]. Results of the
PEACE-1 trial (Table 1) will later add to the weight of
evidence about the effects of AAP, but only results for
men who did not receive docetaxel will be eligible for
inclusion in this current comparison (expected to be
z476/2677; 18%), so would be unlikely to materially
affect our findings. In addition, these results are unlikely
to be available before 2020.4.4. Context
Based on the current and a prior review [10], and
assuming control-group survival of 55%, AAP provides a
14% absolute improvement in 3-year OS compared to an
8% absolute improvement with docetaxel. This crude
comparison does not take into account the different time
frames and patient populations across these trials. An
increase in grade IIIeIV adverse events was observed in
both the abiraterone and docetaxel trials, most
commonly neutropenia with docetaxel and cardiovascu-
lar or hepatic toxicity with abiraterone. However, in both
sets of trials, the incidence of treatment-related deaths
was relatively low. While not a formally powered com-
parison, only the multi-arm STAMPEDE trial can
directly compare the effects of AAP plus ADT with the
effects of docetaxel plus ADT, although this data is not
yet available. A network meta-analysis (NMA) that
makes use of this and all other available direct and indi-
rect comparisons of current therapies for mHSPC may
>75
65-75
<65
LATITUDE
>75
65-75
<65
STAMPEDE
Age (3 categories)
>=70
<70
LATITUDE
>=70
<70
STAMPEDE
Age (2 categories)
by age group
Effect on survival
32/101
70/275
67/221
21/65
79/256
50/179
77/264
92/333
57/170
93/330
events/patients
AAP+ADT
37/101
103/268
97/233
26/72
108/255
84/175
84/235
153/367
67/181
151/321
events/patients
ADT
Favours
AAP+ADT
Favours
ADT
.5 1 2
HR (95% CI)
Interaction
1.24 (1.02, 1.52)
1.12 (0.86, 1.47)
1.41 (1.05, 1.89)
1.54 (1.14, 2.08)
1.34 (0.88, 2.03)
1.80 (1.16, 2.80)
Weight
%
54.42
45.58
52.99
47.01
Greater treatment
effect with older
age groups
Lesser treatment
effect with older
age groups
.5 1 2
Fig. 4. Effect of adding AAP to ADT on overall survival by age group. Labelling and conventions as in Fig. 3. AAP, abiraterone acetate plus
prednisone/prednisolone; ADT, androgen deprivation therapy; CI, confidence interval; HR, hazard ratio.
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relative benefits of AAP and docetaxel being of particular
interest. This NMA is being developed collaboratively as
part of the wider STOPCaP project.
Given the improved OS seen with both AAP and
docetaxel, together with their differing mechanisms of
action, a major question is also whether the effects of
these two agents are additive. This will take some years
to assess, as only the second phase of the PEACE-1 trial
will provide data on ADT plus docetaxel plus AAP.
Therefore, we would actively encourage participation to
this trial. Furthermore, as enzalutamide has been shown
to have a similar clinical effect on androgen signalling in
castration-resistant prostate cancer as AAP, the
ENZAMET trial (NCT02446405) of enzalutamide plus
ADT [19], which has recently completed accrual, and
the ARCHES trial (NCT02677896) which is still
recruiting [20], both of which are stratified by doce-
taxel use, will further augment our knowledge of such
‘triplet therapy’. Also, the ARASENS trial
(NCT02799602) will provide evidence about the effects
of darolutamide in men receiving ADT plus docetaxel
as their standard of care [21]. However, results of
ARCHES and ARASENS are unlikely to be available in
the near future.4.5. Implication(s) of findings
Until evidence about the relative effects of adding AAP
or docetaxel to ADT, or the combination, becomes
available, physicians are likely to have to choose be-
tween AAP and docetaxel. They will need to take ac-
count of efficacy, toxicity and tolerability, and ease of
administration of AAP compared with docetaxel, as well
as cost and access to these agents. A similar choice will
likely need to be considered as part of the ongoing
STAMPEDE comparisons. The collection of IPD from
all relevant trials, as part of the STOPCaP collabora-
tion, will be required to determine definitively if partic-
ular men (for example older or younger) may benefit
more or less from these and other emerging treatments
for mHSPC, to either target effective treatments
appropriately or make them more widely available. IPD
will also be valuable for tackling other important clinical
and scientific questions arising, including the identifi-
cation of surrogate outcomes by building on the Inter-
mediate Clinical Endpoints in Cancer of the Prostate
(ICECaP) initiative in non-metastatic prostate cancer
[24]. Therefore, we are developing the STOPCaP/ICE-
CaP M1 repository of contemporary trials in
mHSPC. This work will be supported by the MRC
(Q = 1.27 on 1 df)
Respiratory disorder
(Q = 4.34 on 1 df)
Musculoskeletal disorder
(Q = 1.85 on 1 df)
Hepatic disorder
(Q = 1.96 on 1 df)
General disorders
(Q = 0.06 on 1 df)
Gastrointestinal disorder
(Q = 0.07 on 1 df)
Cardiac disorder
Trial name
Adverse event type
Subgroup
LATITUDE
STAMPEDE
Subgroup
LATITUDE
STAMPEDE
Subgroup
LATITUDE
STAMPEDE
Subgroup
LATITUDE
STAMPEDE
Subgroup
LATITUDE
STAMPEDE
Subgroup
LATITUDE
STAMPEDE
n/N
ADT+AAP
29/1093
13/597
16/496
102/1093
55/597
47/496
88/1093
50/597
38/496
43/1093
26/597
17/496
44/1093
20/597
24/496
44/1093
18/597
26/496
n/N
ADT
25/1103
15/602
10/501
107/1103
72/602
35/501
27/1103
20/602
7/501
53/1103
39/602
14/501
33/1103
14/602
19/501
14/1103
5/602
9/501
Peto OR (95% CI)
1.17 (0.68, 2.02)
0.96 (0.72, 1.27)
3.09 (2.12, 4.50)
0.81 (0.54, 1.22)
1.36 (0.86, 2.14)
2.93 (1.74, 4.93),
(Q = 0.53 on 1 df)
Vascular disorder
Subgroup
LATITUDE
STAMPEDE
149/1093
127/597
22/496
72/1103
65/602
7/501
2.28 (1.71, 3.03)
(Q = 1.75 on 1 df)
Any G5 adverse events
Subgroup
LATITUDE
STAMPEDE
35/1093
28/597
7/496
26/1103
24/602
2/501
1.37 (0.82, 2.29)
More toxicity with ADT More toxicity with ADT+AAP
0.5 1.0 2.0 4.0 8.0
Fig. 5. Effect of adding AAP to ADT on grade IIIeIV and grade V adverse events. Apart from a Peto OR (rather than hazard ratio)
measure of effect, labelling and conventions are as in Fig. 2. AAP, abiraterone acetate plus prednisone/prednisolone; ADT, androgen
deprivation therapy; CI, confidence interval; OR, odds ratio.
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4.6. Conclusion
Adding AAP to ADT is a highly effective treatment
option for men with mHSPC and offers an alternative to
docetaxel, for men who are starting treatment for the
first time. Future research will need to address which of
these two agents or whether their combination is most
effective, and for whom.
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